Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 8, 2003. The report is a notification of changes in Directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The material changes reported are specific to the shareholdings of Directors and connected persons resulting from two distinct events on October 2, 2003:
- Dividend Reinvestment (US Global BuyDirect Plan):
- Mr. D F McHenry acquired a beneficial interest in 0.2576 Ordinary Share ADRs at $43.95 per ADR.
- Mr. J H McArthur acquired a beneficial interest in 31.5458 Ordinary Share ADRs at $43.95 per ADR.
- Single Company ISA Purchases:
- Mr. J D Coombe purchased 4 Ordinary Shares at £12.66 per share.
- Mrs. G A Coombe (wife of Mr. J D Coombe) purchased 4 Ordinary Shares at £12.66 per share.
- Sir Peter Job purchased 6 Ordinary Shares at £12.66 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely as a regulatory disclosure of insider trading activity.
Key Facts for Investor Verification
- Verify the total number of ADRs and Ordinary Shares held by the named Directors following these transactions.
- Confirm the dividend payment date of October 2, 2003, and the associated reinvestment price of $43.95 per ADR.
- Note that each ADR represents two Ordinary Shares.
- Confirm the purchase price of £12.66 per Ordinary Share for the ISA transactions.